Advertisement

Future Therapies for Trigeminal Autonomic Cephalalgias: Cluster Headache and Related Conditions

  • Peter J. GoadsbyEmail author
  • Lars Edvinsson
Chapter
  • 427 Downloads
Part of the Headache book series (HEAD)

Abstract

The trigeminal autonomic cephalalgias (TACs) are a group of primary headache disorders linked by usually prominent cranial autonomic features [1] that when present are typically lateralized to the side of the pain [2]. The TACs are grouped under section 3 of the current International Classification of Headache Disorders-3 [3]. They consist of cluster headache [4], paroxysmal hemicrania [5], short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT)/cranial autonomic feature (SUNA) [6] and hemicrania continua [7]. These are devastating problems with patients describing the pain of cluster headache as the worst they have ever experienced [8].

References

  1. 1.
    Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic features, including new cases. Brain. 1997;120:193–209.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Nesbitt AD, Goadsby PJ. Cluster Headache. Br Med J. 2012;344:e2407.CrossRefGoogle Scholar
  3. 3.
    Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cepahalalgia. 2018;38:1–211.Google Scholar
  4. 4.
    Hoffmann J, May A. Diagnosis, pathophysiology, and management of cluster headache. Lancet Neurol. 2018;17(1):75–83.CrossRefGoogle Scholar
  5. 5.
    Cittadini E, Matharu MS, Goadsby PJ. Paroxysmal hemicrania: a prospective clinical study of thirty-one cases. Brain. 2008;131:1142–55.CrossRefGoogle Scholar
  6. 6.
    Cohen AS, Matharu MS, Goadsby PJ. Short-lasting Unilateral neuralgiform Headache Attacks with conjunctival injection and Tearing (SUNCT) or cranial Autonomic features (SUNA). A prospective clinical study of SUNCT and SUNA. Brain. 2006;129:2746–60.CrossRefGoogle Scholar
  7. 7.
    Cittadini E, Goadsby PJ. Hemicrania continua: a clinical study of 39 patients with diagnostic implications. Brain. 2010;133:1973–86.CrossRefGoogle Scholar
  8. 8.
    Schor LI. Cluster headache: investigating severity of pain, suicidality, personal burden, access to effective treatment, and demographics among a large International survey sample. Cephalalgia. 2017;37(1S):172.Google Scholar
  9. 9.
    Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache. 2004;44:414–25.CrossRefGoogle Scholar
  10. 10.
    Cohen AS, Burns B, Goadsby PJ. High flow oxygen for treatment of cluster headache. A randomized trial. J Am Med Assoc. 2009;302:2451–7.CrossRefGoogle Scholar
  11. 11.
    Petersen AS, Barloese MC, Lund NL, Jensen RH. Oxygen therapy for cluster headache. A mask comparison trial. A single-blinded, placebo-controlled, crossover study. Cephalalgia. 2017;37:214–24.CrossRefGoogle Scholar
  12. 12.
    Dixon R, Gillotin C, Gibbens M, Posner J, Peck RW. The pharmacokinetics and effects on blood pressure of multiple doses of the novel antimigraine drug zolmitriptan (311C90) in healthy volunteers. Br J Clin Pharmacol. 1997;43:273–81.CrossRefGoogle Scholar
  13. 13.
    Gregor N, Schlesiger C, Akova-Ozturk E, Kraemer C, Husstedt IW, Evers S. Treatment of cluster headache attacks with less than 6 mg subcutaneous sumatriptan. Headache. 2005;45(8):1069–72.CrossRefGoogle Scholar
  14. 14.
    Silberstein SD, Mechtler LL, Kudrow DB, Calhoun AH, McClure C, Saper JR, et al. Non-invasive vagus nerve stimulation for the Acute treatment of cluster headache: findings from the randomized, double-blind, sham-controlled ACT1 study. Headache. 2016;56:1317–32.CrossRefGoogle Scholar
  15. 15.
    Goadsby PJ, de Coo IF, Silver N, Tyagi A, Ahmed F, Gaul C, et al. Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: a randomized, double-blind, sham-controlled ACT2 study. Cephalalgia. 2018;38:959–69.CrossRefGoogle Scholar
  16. 16.
    Nesbitt AD, Marin JCA, Tompkins E, Ruttledge MH, Goadsby PJ. Initial experience with a novel non-invasive vagus nerve stimulation device for the treatment of cluster headache. Neurology (Minneap). 2015;84:1–5.CrossRefGoogle Scholar
  17. 17.
    de Coo IF, Marin J, Silberstein SD, Friedman DI, Gaul C, Tyagi A, et al. Non-invasive vagus nerve stimulation for acute treatment of episodic and chronic cluster headache: pooled analysis of data from two randomised, double-blind, sham-controlled clinical trials. Cephalalgia. 2017;37(1S):175–6.Google Scholar
  18. 18.
    Matharu MS, Levy MJ, Meeran K, Goadsby PJ. Subcutaneous octreotide in cluster headache- randomized placebo-controlled double-blind cross-over study. Ann Neurol. 2004;56:488–94.CrossRefGoogle Scholar
  19. 19.
    McKeage K. Pasireotide in acromegaly: a review. Drugs. 2015;75(9):1039–48.CrossRefGoogle Scholar
  20. 20.
    Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab. 2009;94(2):654–61.CrossRefGoogle Scholar
  21. 21.
    Ambrosini A, Vandenheede M, Rossi P, Aloj F, Sauli E, Pierelli F, et al. Suboccipital injection with a mixture of rapid- and long-acting steroids in cluster headache: a double-blind placebo-controlled study. Pain. 2005;118:92–6.CrossRefGoogle Scholar
  22. 22.
    Leroux E, Valade D, Taifas I, Vicaut E, Chagnon M, Roos C, et al. Suboccipital steroid injections for transitional treatment of patients with more than two cluster headache attacks per day: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011;10:891–7.CrossRefGoogle Scholar
  23. 23.
    Jammes JL. The treatment of cluster headaches with prednisone. Dis Nerv Syst. 1975;36:375–6.PubMedGoogle Scholar
  24. 24.
    Mirzai R, Chang C, Greenspan A, Gershwin ME. The pathogenesis of osteonecrosis and the relationships to corticosteroids. J Asthma. 1999;36:77–95.CrossRefGoogle Scholar
  25. 25.
    Symonds C. A particular variety of headache. Brain. 1956;79:217–32.CrossRefGoogle Scholar
  26. 26.
    Gaul C, Jurgens T. Frovatriptan for prophylactic treatment of cluster headache. Headache. 2011;51:1008–9.CrossRefGoogle Scholar
  27. 27.
    Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Brain. 1994;117:427–34.CrossRefGoogle Scholar
  28. 28.
    Fanciullacci M, Alessandri M, Figini M, Geppetti P, Michelacci S. Increase in plasma calcitonin gene-related peptide from extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain. 1995;60:119–23.CrossRefGoogle Scholar
  29. 29.
    Ong JJY, Wei DY, Goadsby PJ. Recent advances in pharmacotherapy for migraine prevention: from pathophysiology to new drugs. Drugs. 2018;78:411–37.CrossRefGoogle Scholar
  30. 30.
    Oakes TMM, Skljarevski V, Zhang Q, Kielbasa W, Hodsdon ME, Detke HC, et al. Safety of galcanezumab in patients with episodic migraine: a randomized placebo-controlled dose-ranging Phase 2b study. Cephalalgia. 2018;38(6):1015–25.CrossRefGoogle Scholar
  31. 31.
    Martinez JM, Goadsby PJ, Dodick DW, Bardos JN, Oakes TMM, Millen BA, et al. A placebo-controlled study of galcanezumab in patients with episodic cluster headache: from the 8-week double-blind treatment phase. Headache. 2018;58:1289–90.Google Scholar
  32. 32.
    Dodick DW, Goadsby PJ, Spierings ELH, Scherer JC, Sweeney SP, Grayzel DS. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study. Lancet Neurol. 2014;13:885–92.CrossRefGoogle Scholar
  33. 33.
    Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38:1442–54.  https://doi.org/10.1177/0333102418779543.CrossRefPubMedGoogle Scholar
  34. 34.
    Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A, et al. Galcanezumab for episodic migraine prevention: a randomized phase 2b placebo-controlled dose-ranging clinical trial. JAMA Neurol. 2018;75:187–93.CrossRefGoogle Scholar
  35. 35.
    Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol. 2018;75:1080–8.CrossRefGoogle Scholar
  36. 36.
    Dodick DW, Silberstein SD, Bigal ME, Yeung P, Goadsby PJ, Blankenbiller T, et al. Effect of fremanezumab compared with placebo on the prevention of episodic migraine: a randomized clinical trial. JAMA Neurol. 2018;319:1999–2008.CrossRefGoogle Scholar
  37. 37.
    Silberstein SD, Aycardi E, Bigal ME, Blankenbiller T, Dodick DW, Goadsby PJ, et al. Fremanezumab for chonic migraine preventive treatment. N Engl J Med. 2017;377:2113–22.CrossRefGoogle Scholar
  38. 38.
    Goadsby PJ, Schoenen J, Ferrari MD, Silberstein SD, Dodick D. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia. 2006;26:1168–70.CrossRefGoogle Scholar
  39. 39.
    Leone M, Franzini A, Broggi G, Dodick D, Rapoport A, Goadsby PJ, et al. Deep brain stimulation for intractable chronic cluster headache: proposals for patient selection. Cephalalgia. 2004;24:934–7.CrossRefGoogle Scholar
  40. 40.
    Mathew NT, Hurt W. Percutaneous radiofrequency trigeminal gangliorhizolysis in intractable cluster headache. Headache. 1988;28:328–31.CrossRefGoogle Scholar
  41. 41.
    Donnet A, Valade D, Regis J. Gamma knife treatment for refractory cluster headache: prospective open trial. J Neurol Neurosurg Psychiatry. 2005;76:218–21.CrossRefGoogle Scholar
  42. 42.
    Filippini-De Moor GPG, Barendse GAM, van Kleef M, Troost J, de Lange S, Sluijter ME, et al. Retrospective analysis of radiofrequency lesions of the sphenopalatine ganglion in the treatment of 19 cluster headache patients. Pain Clin. 1999;11:285–91.Google Scholar
  43. 43.
    Narouze S, Kapural L, Casanova J, Mekhail N. Sphenopalatine ganglion radiofrequency ablation for the management of chronic cluster headache. Headache. 2009;49:571–7.CrossRefGoogle Scholar
  44. 44.
    Jarrar RG, Black DF, Dodick DW, Davis DH. Outcome of trigeminal nerve section in the treatment of chronic cluster headache. Neurology. 2003;60:1360–2.CrossRefGoogle Scholar
  45. 45.
    May A, Bahra A, Buchel C, Frackowiak RS, Goadsby PJ. Hypothalamic activation in cluster headache attacks. Lancet. 1998;352:275–8.CrossRefGoogle Scholar
  46. 46.
    Leone M, Franzini A, Bussone G. Stereotatic stimulation of the posterior hypothalamic gray matter in a patient with intractable cluster headache. N Engl J Med. 2001;345:1428–9.CrossRefGoogle Scholar
  47. 47.
    Leone M, Franzini A, Cecchini AP, Broggi G, Bussone G. Hypothalamic deep brain stimulation in the treatment of chronic cluster headache. Ther Adv Neurol Disord. 2010;3(3):187–95.CrossRefGoogle Scholar
  48. 48.
    Schoenen J, Di Clemente L, Vandenheede M, Fumal A, De Pasqua V, Mouchamps M, et al. Hypothalamic stimulation in chronic cluster headache: a pilot study of efficacy and mode of action. Brain. 2005;128:940–7.CrossRefGoogle Scholar
  49. 49.
    Fontaine D, Lazorthes Y, Mertens P, Blond S, Geraud G, Fabre N, et al. Safety and efficacy of deep brain stimulation in refractory cluster headache: a randomized placebo-controlled double-blind trial followed by a 1-year open extension. J Headache Pain. 2010;11:23–31.CrossRefGoogle Scholar
  50. 50.
    Burns B, Watkins L, Goadsby PJ. Successful treatment of medically intractable cluster headache using occipital nerve stimulation (ONS). Lancet. 2007;369:1099–106.CrossRefGoogle Scholar
  51. 51.
    Magis D, Allena M, Bolla M, De Pasqua V, Remacle JM, Schoenen J. Occipital nerve stimulation for drug-resistant chronic cluster headache: a prospective pilot study. Lancet Neurol. 2007;6:314–21.CrossRefGoogle Scholar
  52. 52.
    Burns B, Watkins L, Goadsby PJ. Treatment of intractable chronic cluster headache by occipital nerve stimulation in 14 patients. Neurology. 2009;72:341–5.CrossRefGoogle Scholar
  53. 53.
    Gray H. Anatomy of the human body. Philadelphia: Lea & Febiger; 1918.. www.bartleby.com/107/ CrossRefGoogle Scholar
  54. 54.
    May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiological implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab. 1999;19:115–27.CrossRefGoogle Scholar
  55. 55.
    Goadsby PJ, Lambert GA, Lance JW. The peripheral pathway for extracranial vasodilatation in the cat. J Auton Nerv Syst. 1984;10:145–55.CrossRefGoogle Scholar
  56. 56.
    Sluder G. The role of the sphenopalatine (or Meckle’s) ganglion in nasal headaches. NY Med J. 1908;87:989–90.Google Scholar
  57. 57.
    Ansarinia M, Rezai A, Tepper SJ, Steiner CP, Stump J, Stanton-Hicks M, et al. Electrical stimulation of sphenopalatine ganglion for acute treatment of cluster headaches. Headache. 2010;50(7):1164–74.CrossRefGoogle Scholar
  58. 58.
    Schoenen J, Jensen RH, Lanteri-Minet M, Lainez JM, Gaul C, Goodman AM, et al. Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: a randomized, sham-controlled study. Cephalalgia. 2013;33:816–30.CrossRefGoogle Scholar
  59. 59.
    Goadsby PJ, Sahai-Srivastava S, Kezirian EJ, Calhoun AH, Matthews DC, McAllister PJ, et al. Sham-controlled study of sphenopalatine ganglion stimulation for chronic cluster headache. Headache. 2018;58:1316–7.Google Scholar
  60. 60.
    Jurgens TP, Barloese M, May A, Lainez JM, Schoenen J, Gaul C, et al. Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache. Cephalalgia. 2017;37:423–34.CrossRefGoogle Scholar
  61. 61.
    Tso AR, Marin JCA, Goadsby PJ. Non-invasive vagus nerve stimulation for treatment of indomethacin-sensitive headaches. JAMA Neurol. 2017;74:1266–7.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.NIHR-Wellcome Trust King’s Clinical Research Facility & SLaM Biomedical Research CentreKing’s College LondonLondonUK
  2. 2.Department of Internal MedicineUniversity of LundLundSweden

Personalised recommendations